CAPN10

Across TCGA pan-cancer cohorts, CAPN10 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CAPN10 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CAPN10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CAPN10 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRC, SCLC, and LIHC are the cancer types where CAPN10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.203	0.789	.009	24	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →
LIHC	OS	Median	All	0.166	0.688	.033	6	view →
STAD	OS	Median	III,IV	0.164	0.633	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.834	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CAPN10–KIRC (OS)

Open the KIRC breakdown →